HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
HIVAIDSKaposi's SarcomaHuman Herpesvirus 8
Interventions
DRUG

Generic HAART Triomune : d4T, 3TC, NVP

Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)

DRUG

Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV

Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.

Trial Locations (1)

4001

Department of Dermatology, King Edward VIII Hospital, Durban

All Listed Sponsors
collaborator

AIDS Care Research in Africa

OTHER

collaborator

National Research Foundation, Singapore

OTHER_GOV

collaborator

AIDS Malignancy Consortium

NETWORK

collaborator

Cipla Medpro

INDUSTRY

collaborator

Dermatological Society of South Africa

UNKNOWN

lead

University of KwaZulu

OTHER

NCT00380770 - HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT | Biotech Hunter | Biotech Hunter